Genomic tests are extensively utilized in patients with hormone receptor-positive early breast cancer or limited nodal disease to determine whether they may benefit from additional adjuvant chemotherapy or whether they could be successfully treated with endocrine therapy only. This evidence concerns the gene NR4A1 and breast carcinoma.